Drug Treatment Availability and Satisfaction Survey
-
by
mervyn
Towards the end of 2025 Eltrombopag (one of a class of drugs for ITP known as TPO-RAs) came off patent and a generic version was made available at a greatly reduced cost to the NHS.
At the time it was agreed that ‘Patients currently stabilised/established on a different TPO RA should continue with this treatment’.
At the ITP Support Association we have been receiving reports from some patients that they are being advised they will be taken off there current (TPO-RA) treatment and moved to Generic Eltrombopag.
This survey is designed to identify how much of this ‘switching’ is taking place.
With this survey, no user or identification information is stored The results of this survey will be published on our website and social media channels.
This survey will close on 14th April 2026.
To complete our survey please click this link: ITPSA Drug Treatment Availability Survey
